Association of glycogen synthase kinase‑3β with Parkinson's disease (Review)

Forno LS: Neuropathology of Parkinson’s disease. J Neuropathol Exp Neurol. 55:259–272. 1996.

McNaught KS and Olanow CW: Protein aggregation in the pathogenesis of familial and sporadic Parkinson’s disease. Neurobiol Aging. 27:530–545. 2006.

Martinez-Vicente M, Talloczy Z, Kaushik S, et al: Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J Clin Invest. 118:777–788. 2008.PubMed/NCBI

Keeney PM, Xie J, Capaldi RA and Bennett JP Jr: Parkinson’s disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J Neurosci. 26:5256–5264. 2006.

Li DW, Li GR, Lu Y, et al: alpha-lipoic acid protects dopaminergic neurons against MPP+-induced apoptosis by attenuating reactive oxygen species formation. Int J Mol Med. 32:108–114. 2013.PubMed/NCBI

Rasola A and Bernardi P: Mitochondrial permeability transition in Ca(²⁺)-dependent apoptosis and necrosis. Cell Calcium. 50:222–233. 2011. View Article : Google Scholar

Parker WD Jr, Boyson SJ and Parks JK: Abnormalities of the electron transport chain in idiopathic Parkinson’s disease. Ann Neurol. 26:719–723. 1989.

Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB and Marsden CD: Mitochondrial complex I deficiency in Parkinson’s disease. Lancet. 1:12691989.

Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV and Greenamyre JT: Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat Neurosci. 3:1301–1306. 2000.

Cannon JR, Tapias V, Na HM, Honick AS, Drolet RE and Greenamyre JT: A highly reproducible rotenone model of Parkinson’s disease. Neurobiol Dis. 34:279–290. 2009.PubMed/NCBI

Hantraye P, Brouillet E, Ferrante R, et al: Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nat Med. 2:1017–1021. 1996. View Article : Google Scholar : PubMed/NCBI

Shang T, Kotamraju S, Kalivendi SV, Hillard CJ and Kalyanaraman B: 1-Methyl-4-phenylpyridinium-induced apoptosis in cerebellar granule neurons is mediated by transferrin receptor iron-dependent depletion of tetrahydrobiopterin and neuronal nitric-oxide synthase-derived superoxide. J Biol Chem. 279:19099–19112. 2004. View Article : Google Scholar

Hartley A, Stone JM, Heron C, Cooper JM and Schapira AH: Complex I inhibitors induce dose-dependent apoptosis in PC12 cells: relevance to Parkinson’s disease. J Neurochem. 63:1987–1990. 1994.PubMed/NCBI

Kreutzberg GW: Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 19:312–318. 1996. View Article : Google Scholar : PubMed/NCBI

Monahan AJ, Warren M and Carvey PM: Neuroinflammation and peripheral immune infiltration in Parkinson’s disease: an autoimmune hypothesis. Cell Transplant. 17:363–372. 2008.

Hirsch EC and Hunot S: Neuroinflammation in Parkinson’s disease: a target for neuroprotection? Lancet Neurol. 8:382–397. 2009.

Gao HM, Zhou H, Zhang F, Wilson BC, Kam W and Hong JS: HMGB1 acts on microglia Mac1 to mediate chronic neuroinflammation that drives progressive neurodegeneration. J Neurosci. 31:1081–1092. 2011. View Article : Google Scholar : PubMed/NCBI

McGeer PL, Schwab C, Parent A and Doudet D: Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Ann Neurol. 54:599–604. 2003.

Block ML, Zecca L and Hong JS: Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci. 8:57–69. 2007. View Article : Google Scholar : PubMed/NCBI

Gao HM, Liu B, Zhang W and Hong JS: Novel anti-inflammatory therapy for Parkinson’s disease. Trends Pharmacol Sci. 24:395–401. 2003.

Wu DC, Teismann P, Tieu K, et al: NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson’s disease. Proc Natl Acad Sci USA. 100:6145–6150. 2003.

Zhang F, Qian L, Flood PM, Shi JS, Hong JS and Gao HM: Inhibition of IkappaB kinase-beta protects dopamine neurons against lipopolysaccharide-induced neurotoxicity. J Pharmacol Exp Ther. 333:822–833. 2010. View Article : Google Scholar : PubMed/NCBI

Wang W, Yang Y, Ying C, et al: Inhibition of glycogen synthase kinase-3beta protects dopaminergic neurons from MPTP toxicity. Neuropharmacology. 52:1678–1684. 2007. View Article : Google Scholar : PubMed/NCBI

King TD, Bijur GN and Jope RS: Caspase-3 activation induced by inhibition of mitochondrial complex I is facilitated by glycogen synthase kinase-3beta and attenuated by lithium. Brain Res. 919:106–114. 2001. View Article : Google Scholar : PubMed/NCBI

Woodgett JR: Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J. 9:2431–2438. 1990.PubMed/NCBI

Parker PJ, Embi N, Caudwell FB and Cohen P: Glycogen synthase from rabbit skeletal muscle. State of phosphorylation of the seven phosphoserine residues in vivo in the presence and absence of adrenaline. Eur J Biochem. 124:47–55. 1982. View Article : Google Scholar : PubMed/NCBI

Jope RS and Johnson GV: The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci. 29:95–102. 2004. View Article : Google Scholar : PubMed/NCBI

Kockeritz L, Doble B, Patel S and Woodgett JR: Glycogen synthase kinase-3 - an overview of an over-achieving protein kinase. Curr Drug Targets. 7:1377–1388. 2006. View Article : Google Scholar : PubMed/NCBI

Miura T, Tanno M and Sato T: Mitochondrial kinase signalling pathways in myocardial protection from ischaemia/reperfusion-induced necrosis. Cardiovasc Res. 88:7–15. 2010. View Article : Google Scholar : PubMed/NCBI

Medina M, Garrido JJ and Wandosell FG: Modulation of GSK-3 as a Therapeutic Strategy on Tau Pathologies. Front Mol Neurosci. 4:242011. View Article : Google Scholar : PubMed/NCBI

King MR, Anderson NJ, Guernsey LS and Jolivalt CG: Glycogen synthase kinase-3 inhibition prevents learning deficits in diabetic mice. J Neurosci Res. 91:506–514. 2013. View Article : Google Scholar : PubMed/NCBI

Zheng H, Li W, Wang Y, et al: Glycogen synthase kinase-3 beta regulates Snail and beta-catenin expression during Fas-induced epithelial-mesenchymal transition in gastrointestinal cancer. Eur J Cancer. 2013. View Article : Google Scholar

Dajani R, Fraser E, Roe SM, et al: Crystal structure of glycogen synthase kinase 3 beta: structural basis for phosphate-primed substrate specificity and autoinhibition. Cell. 105:721–732. 2001.PubMed/NCBI

Xavier IJ, Mercier PA, McLoughlin CM, Ali A, Woodgett JR and Ovsenek N: Glycogen synthase kinase 3beta negatively regulates both DNA-binding and transcriptional activities of heat shock factor 1. J Biol Chem. 275:29147–29152. 2000. View Article : Google Scholar : PubMed/NCBI

Bijur GN and Jope RS: Proapoptotic stimuli induce nuclear accumulation of glycogen synthase kinase-3 beta. J Biol Chem. 276:37436–37442. 2001. View Article : Google Scholar : PubMed/NCBI

Bijur GN and Jope RS: Glycogen synthase kinase-3 beta is highly activated in nuclei and mitochondria. Neuroreport. 14:2415–2419. 2003. View Article : Google Scholar : PubMed/NCBI

Hoshi M, Sato M, Kondo S, et al: Different localization of tau protein kinase I/glycogen synthase kinase-3 beta from glycogen synthase kinase-3 alpha in cerebellum mitochondria. J Biochem. 118:683–685. 1995.PubMed/NCBI

Senatorov VV, Ren M, Kanai H, Wei H and Chuang DM: Short-term lithium treatment promotes neuronal survival and proliferation in rat striatum infused with quinolinic acid, an excitotoxic model of Huntington’s disease. Mol Psychiatry. 9:371–385. 2004.PubMed/NCBI

Bijur GN, De Sarno P and Jope RS: Glycogen synthase kinase-3beta facilitates staurosporine- and heat shock-induced apoptosis. Protection by lithium. J Biol Chem. 275:7583–7590. 2000. View Article : Google Scholar : PubMed/NCBI

Alvarez AR, Godoy JA, Mullendorff K, Olivares GH, Bronfman M and Inestrosa NC: Wnt-3a overcomes beta-amyloid toxicity in rat hippocampal neurons. Exp Cell Res. 297:186–196. 2004. View Article : Google Scholar : PubMed/NCBI

Wu Y, Shang Y, Sun S, Liang H and Liu R: Erythropoietin prevents PC12 cells from 1-methyl-4-phenylpyridinium ion-induced apoptosis via the Akt/GSK-3beta/caspase-3 mediated signaling pathway. Apoptosis. 12:1365–1375. 2007. View Article : Google Scholar : PubMed/NCBI

Petit-Paitel A, Brau F, Cazareth J and Chabry J: Involvment of cytosolic and mitochondrial GSK-3beta in mitochondrial dysfunction and neuronal cell death of MPTP/MPP-treated neurons. PLoS One. 4:e54912009. View Article : Google Scholar : PubMed/NCBI

King TD, Clodfelder-Miller B, Barksdale KA and Bijur GN: Unregulated mitochondrial GSK3beta activity results in NADH: ubiquinone oxidoreductase deficiency. Neurotox Res. 14:367–382. 2008. View Article : Google Scholar : PubMed/NCBI

Huang WC, Lin YS, Wang CY, et al: Glycogen synthase kinase-3 negatively regulates anti-inflammatory interleukin-10 for lipopolysaccharide-induced iNOS/NO biosynthesis and RANTES production in microglial cells. Immunology. 128:e275–e286. 2009. View Article : Google Scholar : PubMed/NCBI

Yuskaitis CJ and Jope RS: Glycogen synthase kinase-3 regulates microglial migration, inflammation, and inflammation-induced neurotoxicity. Cell Signal. 21:264–273. 2009. View Article : Google Scholar : PubMed/NCBI

Camello-Almaraz C, Gomez-Pinilla PJ, Pozo MJ and Camello PJ: Mitochondrial reactive oxygen species and Ca²⁺signaling. Am J Physiol Cell Physiol. 291:C1082–C1088. 2006. View Article : Google Scholar : PubMed/NCBI

Grivennikova VG and Vinogradov AD: Generation of superoxide by the mitochondrial Complex I. Biochim Biophys Acta. 1757:553–561. 2006. View Article : Google Scholar : PubMed/NCBI

Abou-Sleiman PM, Muqit MM and Wood NW: Expanding insights of mitochondrial dysfunction in Parkinson’s disease. Nat Rev Neurosci. 7:207–219. 2006.

Langston JW, Ballard P, Tetrud JW and Irwin I: Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 219:979–980. 1983. View Article : Google Scholar : PubMed/NCBI

Chiba K, Trevor A and Castagnoli N Jr: Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun. 120:574–578. 1984. View Article : Google Scholar : PubMed/NCBI

Javitch JA, D’Amato RJ, Strittmatter SM and Snyder SH: Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA. 82:2173–2177. 1985. View Article : Google Scholar

Bindoff LA, Birch-Machin M, Cartlidge NE, Parker WD Jr and Turnbull DM: Mitochondrial function in Parkinson’s disease. Lancet. 2:491989.

Kussmaul L and Hirst J: The mechanism of superoxide production by NADH: ubiquinone oxidoreductase (complex I) from bovine heart mitochondria. Proc Natl Acad Sci USA. 103:7607–7612. 2006. View Article : Google Scholar : PubMed/NCBI

Sipos I, Tretter L and Adam-Vizi V: Quantitative relationship between inhibition of respiratory complexes and formation of reactive oxygen species in isolated nerve terminals. J Neurochem. 84:112–118. 2003. View Article : Google Scholar : PubMed/NCBI

Murphy MP: How mitochondria produce reactive oxygen species. Biochem J. 417:1–13. 2009. View Article : Google Scholar : PubMed/NCBI

Cassarino DS, Fall CP, Swerdlow RH, et al: Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson’s disease. Biochim Biophys Acta. 1362:77–86. 1997.PubMed/NCBI

Pastorino JG, Hoek JB and Shulga N: Activation of glycogen synthase kinase 3beta disrupts the binding of hexokinase II to mitochondria by phosphorylating voltage-dependent anion channel and potentiates chemotherapy-induced cytotoxicity. Cancer Res. 65:10545–10554. 2005. View Article : Google Scholar

Watcharasit P, Bijur GN, Song L, Zhu J, Chen X and Jope RS: Glycogen synthase kinase-3beta (GSK3beta) binds to and promotes the actions of p53. J Biol Chem. 278:48872–48879. 2003. View Article : Google Scholar : PubMed/NCBI

Valerio A, Bertolotti P, Delbarba A, et al: Glycogen synthase kinase-3 inhibition reduces ischemic cerebral damage, restores impaired mitochondrial biogenesis and prevents ROS production. J Neurochem. 116:1148–1159. 2011. View Article : Google Scholar

Vila M and Przedborski S: Targeting programmed cell death in neurodegenerative diseases. Nat Rev Neurosci. 4:365–375. 2003. View Article : Google Scholar : PubMed/NCBI

Perier C, Tieu K, Guegan C, et al: Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage. Proc Natl Acad Sci USA. 102:19126–19131. 2005. View Article : Google Scholar : PubMed/NCBI

Roucou X and Martinou JC: Conformational change of Bax: a question of life or death. Cell Death Differ. 8:875–877. 2001. View Article : Google Scholar : PubMed/NCBI

Obame FN, Plin-Mercier C, Assaly R, et al: Cardioprotective effect of morphine and a blocker of glycogen synthase kinase 3 beta, SB216763 [3-(2,4-dichlorophenyl)-4(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione], via inhibition of the mitochondrial permeability transition pore. J Pharmacol Exp Ther. 326:252–258. 2008.PubMed/NCBI

Nishihara M, Miura T, Miki T, et al: Modulation of the mitochondrial permeability transition pore complex in GSK-3beta-mediated myocardial protection. J Mol Cell Cardiol. 43:564–570. 2007. View Article : Google Scholar : PubMed/NCBI

Feng J, Lucchinetti E, Ahuja P, Pasch T, Perriard JC and Zaugg M: Isoflurane postconditioning prevents opening of the mitochondrial permeability transition pore through inhibition of glycogen synthase kinase 3beta. Anesthesiology. 103:987–995. 2005. View Article : Google Scholar

Park SS, Zhao H, Mueller RA and Xu Z: Bradykinin prevents reperfusion injury by targeting mitochondrial permeability transition pore through glycogen synthase kinase 3beta. J Mol Cell Cardiol. 40:708–716. 2006. View Article : Google Scholar : PubMed/NCBI

Gomez L, Paillard M, Thibault H, Derumeaux G and Ovize M: Inhibition of GSK3beta by postconditioning is required to prevent opening of the mitochondrial permeability transition pore during reperfusion. Circulation. 117:2761–2768. 2008. View Article : Google Scholar : PubMed/NCBI

Zhou K, Zhang L, Xi J, Tian W and Xu Z: Ethanol prevents oxidant-induced mitochondrial permeability transition pore opening in cardiac cells. Alcohol Alcohol. 44:20–24. 2009. View Article : Google Scholar : PubMed/NCBI

Youdim MB and Arraf Z: Prevention of MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) dopaminergic neurotoxicity in mice by chronic lithium: involvements of Bcl-2 and Bax. Neuropharmacology. 46:1130–1140. 2004. View Article : Google Scholar : PubMed/NCBI

Linseman DA, Butts BD, Precht TA, et al: Glycogen synthase kinase-3beta phosphorylates Bax and promotes its mitochondrial localization during neuronal apoptosis. J Neurosci. 24:9993–10002. 2004. View Article : Google Scholar : PubMed/NCBI

Maurer U, Charvet C, Wagman AS, Dejardin E and Green DR: Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell. 21:749–760. 2006. View Article : Google Scholar : PubMed/NCBI

Tsujimoto Y and Shimizu S: VDAC regulation by the Bcl-2 family of proteins. Cell Death Differ. 7:1174–1181. 2000. View Article : Google Scholar : PubMed/NCBI

Martinou JC and Green DR: Breaking the mitochondrial barrier. Nat Rev Mol Cell Biol. 2:63–67. 2001. View Article : Google Scholar : PubMed/NCBI

Armstrong JS: Mitochondrial membrane permeabilization: the sine qua non for cell death. Bioessays. 28:253–260. 2006. View Article : Google Scholar : PubMed/NCBI

Gollapudi S, McCormick MJ and Gupta S: Changes in mitochondrial membrane potential and mitochondrial mass occur independent of the activation of caspase-8 and caspase-3 during CD95-mediated apoptosis in peripheral blood T cells. Int J Oncol. 22:597–600. 2003.PubMed/NCBI

Tan J, Zhuang L, Leong HS, Iyer NG, Liu ET and Yu Q: Pharmacologic modulation of glycogen synthase kinase-3beta promotes p53-dependent apoptosis through a direct Bax-mediated mitochondrial pathway in colorectal cancer cells. Cancer Res. 65:9012–9020. 2005. View Article : Google Scholar

Chen G, Zeng WZ, Yuan PX, et al: The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem. 72:879–882. 1999. View Article : Google Scholar : PubMed/NCBI

Kaga S, Zhan L, Altaf E and Maulik N: Glycogen synthase kinase-3beta/beta-catenin promotes angiogenic and anti-apoptotic signaling through the induction of VEGF, Bcl-2 and survivin expression in rat ischemic preconditioned myocardium. J Mol Cell Cardiol. 40:138–147. 2006. View Article : Google Scholar

Chen RW and Chuang DM: Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. J Biol Chem. 274:6039–6042. 1999. View Article : Google Scholar : PubMed/NCBI

Ohori K, Miura T, Tanno M, et al: Ser9 phosphorylation of mitochondrial GSK-3beta is a primary mechanism of cardiomyocyte protection by erythropoietin against oxidant-induced apoptosis. Am J Physiol Heart Circ Physiol. 295:H2079–H2086. 2008. View Article : Google Scholar : PubMed/NCBI

Ge XH, Zhu GJ, Geng DQ, Zhang ZJ and Liu CF: Erythropoietin attenuates 6-hydroxydopamine-induced apoptosis via glycogen synthase kinase 3b-mediated mitochondrial translocation of Bax in PC12 cells. Neurol Sci. 33:1249–1256. 2012. View Article : Google Scholar

Ngok-Ngam P, Watcharasit P, Thiantanawat A and Satayavivad J: Pharmacological inhibition of GSK3 attenuates DNA damage-induced apoptosis via reduction of p53 mitochondrial translocation and Bax oligomerization in neuroblastoma SH-SY5Y cells. Cell Mol Biol Lett. 18:58–74. 2013. View Article : Google Scholar : PubMed/NCBI

Samii A, Nutt JG and Ransom BR: Parkinson’s disease. Lancet. 363:1783–1793. 2004.

Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R and Goedert M: Alpha-synuclein in Lewy bodies. Nature. 388:839–840. 1997. View Article : Google Scholar : PubMed/NCBI

Singleton AB, Farrer M, Johnson J, et al: alpha-Synuclein locus triplication causes Parkinson’s disease. Science. 302:8412003.

Liu D, Jin L, Wang H, et al: Silencing alpha-synuclein gene expression enhances tyrosine hydroxylase activity in MN9D cells. Neurochem Res. 33:1401–1409. 2008. View Article : Google Scholar : PubMed/NCBI

Baptista MJ, O’Farrell C, Daya S, et al: Co-ordinate transcriptional regulation of dopamine synthesis genes by alpha-synuclein in human neuroblastoma cell lines. J Neurochem. 85:957–968. 2003. View Article : Google Scholar : PubMed/NCBI

Perez RG, Waymire JC, Lin E, Liu JJ, Guo F and Zigmond MJ: A role for alpha-synuclein in the regulation of dopamine biosynthesis. J Neurosci. 22:3090–3099. 2002.

Yu S, Zuo X, Li Y, et al: Inhibition of tyrosine hydroxylase expression in alpha-synuclein-transfected dopaminergic neuronal cells. Neurosci Lett. 367:34–39. 2004. View Article : Google Scholar : PubMed/NCBI

Danzer KM, Haasen D, Karow AR, et al: Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci. 27:9220–9232. 2007. View Article : Google Scholar : PubMed/NCBI

Periquet M, Fulga T, Myllykangas L, Schlossmacher MG and Feany MB: Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo. J Neurosci. 27:3338–3346. 2007. View Article : Google Scholar : PubMed/NCBI

Desplats P, Lee HJ, Bae EJ, et al: Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci USA. 106:13010–13015. 2009. View Article : Google Scholar : PubMed/NCBI

Masliah E, Rockenstein E, Veinbergs I, et al: Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science. 287:1265–1269. 2000. View Article : Google Scholar : PubMed/NCBI

Parihar MS, Parihar A, Fujita M, Hashimoto M and Ghafourifar P: Mitochondrial association of alpha-synuclein causes oxidative stress. Cell Mol Life Sci. 65:1272–1284. 2008. View Article : Google Scholar : PubMed/NCBI

Parihar MS, Parihar A, Fujita M, Hashimoto M and Ghafourifar P: Alpha-synuclein overexpression and aggregation exacerbates impairment of mitochondrial functions by augmenting oxidative stress in human neuroblastoma cells. Int J Biochem Cell Biol. 41:2015–2024. 2009. View Article : Google Scholar

Hsu LJ, Sagara Y, Arroyo A, et al: alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol. 157:401–410. 2000. View Article : Google Scholar : PubMed/NCBI

Feng LR, Federoff HJ, Vicini S and Maguire-Zeiss KA: Alpha-synuclein mediates alterations in membrane conductance: a potential role for alpha-synuclein oligomers in cell vulnerability. Eur J Neurosci. 32:10–17. 2010. View Article : Google Scholar : PubMed/NCBI

Lee EJ, Woo MS, Moon PG, et al: Alpha-synuclein activates microglia by inducing the expressions of matrix metalloproteinases and the subsequent activation of protease-activated receptor-1. J Immunol. 185:615–623. 2010. View Article : Google Scholar : PubMed/NCBI

Su X, Federoff HJ and Maguire-Zeiss KA: Mutant alpha-synuclein overexpression mediates early proinflammatory activity. Neurotox Res. 16:238–254. 2009. View Article : Google Scholar : PubMed/NCBI

Theodore S, Cao S, McLean PJ and Standaert DG: Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J Neuropathol Exp Neurol. 67:1149–1158. 2008. View Article : Google Scholar

Kozikowski AP, Gaisina IN, Petukhov PA, et al: Highly potent and specific GSK-3beta inhibitors that block tau phosphorylation and decrease alpha-synuclein protein expression in a cellular model of Parkinson’s disease. ChemMedChem. 1:256–266. 2006.PubMed/NCBI

Haggerty T, Credle J, Rodriguez O, et al: Hyperphosphorylated Tau in an alpha-synuclein-overexpressing transgenic model of Parkinson’s disease. Eur J Neurosci. 33:1598–1610. 2011.PubMed/NCBI

Wills J, Jones J, Haggerty T, Duka V, Joyce JN and Sidhu A: Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson’s disease brains with and without dementia. Exp Neurol. 225:210–218. 2010.

Cho JH and Johnson GV: Glycogen synthase kinase 3 beta induces caspase-cleaved tau aggregation in situ. J Biol Chem. 279:54716–54723. 2004. View Article : Google Scholar : PubMed/NCBI

Peng JH, Zhang CE, Wei W, Hong XP, Pan XP and Wang JZ: Dehydroevodiamine attenuates tau hyperphosphorylation and spatial memory deficit induced by activation of glycogen synthase kinase-3 in rats. Neuropharmacology. 52:1521–1527. 2007. View Article : Google Scholar : PubMed/NCBI

Chun W and Johnson GV: Activation of glycogen synthase kinase 3beta promotes the intermolecular association of tau. The use of fluorescence resonance energy transfer microscopy. J Biol Chem. 282:23410–23417. 2007. View Article : Google Scholar : PubMed/NCBI

Greco SJ, Sarkar S, Casadesus G, et al: Leptin inhibits glycogen synthase kinase-3beta to prevent tau phosphorylation in neuronal cells. Neurosci Lett. 455:191–194. 2009. View Article : Google Scholar : PubMed/NCBI

Crouch PJ, Hung LW, Adlard PA, et al: Increasing Cu bioavailability inhibits Abeta oligomers and tau phosphorylation. Proc Natl Acad Sci USA. 106:381–386. 2009. View Article : Google Scholar : PubMed/NCBI

Engel T, Lucas JJ, Gomez-Ramos P, Moran MA, Avila J and Hernandez F: Cooexpression of FTDP-17 tau and GSK-3beta in transgenic mice induce tau polymerization and neurodegeneration. Neurobiol Aging. 27:1258–1268. 2006. View Article : Google Scholar : PubMed/NCBI

Engel T, Hernandez F, Avila J and Lucas JJ: Full reversal of Alzheimer’s disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J Neurosci. 26:5083–5090. 2006.

Perez M, Hernandez F, Lim F, Diaz-Nido J and Avila J: Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J Alzheimers Dis. 5:301–308. 2003.PubMed/NCBI

Nakashima H, Ishihara T, Suguimoto P, et al: Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies. Acta Neuropathol. 110:547–556. 2005. View Article : Google Scholar : PubMed/NCBI

Engel T, Goni-Oliver P, Lucas JJ, Avila J and Hernandez F: Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J Neurochem. 99:1445–1455. 2006. View Article : Google Scholar : PubMed/NCBI

Gao HM and Hong JS: Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol. 29:357–365. 2008. View Article : Google Scholar : PubMed/NCBI

Kim SU and de Vellis J: Microglia in health and disease. J Neurosci Res. 81:302–313. 2005. View Article : Google Scholar : PubMed/NCBI

Mrak RE and Griffin WS: Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging. 26:349–354. 2005. View Article : Google Scholar : PubMed/NCBI

McGeer PL and McGeer EG: Glial reactions in Parkinson’s disease. Mov Disord. 23:474–483. 2008.

Ouchi Y, Yagi S, Yokokura M and Sakamoto M: Neuroinflammation in the living brain of Parkinson’s disease. Parkinsonism Relat Disord. 15 Suppl 3:S200–S204. 2009.

Hunot S, Dugas N, Faucheux B, et al: FcepsilonRII/CD23 is expressed in Parkinson’s disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J Neurosci. 19:3440–3447. 1999.PubMed/NCBI

Mogi M, Harada M, Narabayashi H, Inagaki H, Minami M and Nagatsu T: Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson’s disease. Neurosci Lett. 211:13–16. 1996.PubMed/NCBI

Koziorowski D, Tomasiuk R, Szlufik S and Friedman A: Inflammatory cytokines and NT-proCNP in Parkinson’s disease patients. Cytokine. 60:762–766. 2012.

Przedborski S: Inflammation and Parkinson’s disease pathogenesis. Mov Disord. 25 Suppl 1:S55–S57. 2010.

Frankola KA, Greig NH, Luo W and Tweedie D: Targeting TNF-alpha to elucidate and ameliorate neuroinflammation in neurodegenerative diseases. CNS Neurol Disord Drug Targets. 10:391–403. 2011. View Article : Google Scholar : PubMed/NCBI

Qian L, Flood PM and Hong JS: Neuroinflammation is a key player in Parkinson’s disease and a prime target for therapy. J Neural Transm. 117:971–979. 2010.

Lofrumento DD, Nicolardi G, Cianciulli A, et al: Neuroprotective effects of resveratrol in an MPTP mouse model of Parkinson’s-like disease: Possible role of SOCS-1 in reducing pro-inflammatory responses. Innate Immun. 2013.PubMed/NCBI

Martin M, Rehani K, Jope RS and Michalek SM: Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol. 6:777–784. 2005. View Article : Google Scholar : PubMed/NCBI

Jope RS, Yuskaitis CJ and Beurel E: Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res. 32:577–595. 2007. View Article : Google Scholar : PubMed/NCBI

Beurel E and Jope RS: Lipopolysaccharide-induced interleukin-6 production is controlled by glycogen synthase kinase-3 and STAT3 in the brain. J Neuroinflammation. 6:92009. View Article : Google Scholar : PubMed/NCBI

Cheng YL, Wang CY, Huang WC, et al: Staphylococcus aureus induces microglial inflammation via a glycogen synthase kinase 3beta-regulated pathway. Infect Immun. 77:4002–4008. 2009. View Article : Google Scholar : PubMed/NCBI

Wang MJ, Huang HY, Chen WF, Chang HF and Kuo JS: Glycogen synthase kinase-3beta inactivation inhibits tumor necrosis factor-alpha production in microglia by modulating nuclear factor kappaB and MLK3/JNK signaling cascades. J Neuroinflammation. 7:992010. View Article : Google Scholar

Colasanti M, Persichini T, Di Pucchio T, Gremo F and Lauro GM: Human ramified microglial cells produce nitric oxide upon Escherichia coli lipopolysaccharide and tumor necrosis factor alpha stimulation. Neurosci Lett. 200:144–146. 1995. View Article : Google Scholar

Block ML and Hong JS: Chronic microglial activation and progressive dopaminergic neurotoxicity. Biochem Soc Trans. 35:1127–1132. 2007. View Article : Google Scholar : PubMed/NCBI

Członkowska A, Kohutnicka M, Kurkowska-Jastrzebska I and Członkowski A: Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced Parkinson’s disease mice model. Neurodegeneration. 5:137–143. 1996.

Przedborski S and Vila M: The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson’s disease. Ann NY Acad Sci. 991:189–198. 2003.PubMed/NCBI

Duka T, Duka V, Joyce JN and Sidhu A: Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson’s disease models. FASEB J. 23:2820–2830. 2009.PubMed/NCBI

Watcharasit P, Thiantanawat A and Satayavivad J: GSK3 promotes arsenite-induced apoptosis via facilitation of mitochondria disruption. J Appl Toxicol. 28:466–474. 2008. View Article : Google Scholar : PubMed/NCBI

Cookson MR: The biochemistry of Parkinson’s disease. Annu Rev Biochem. 74:29–52. 2005.